Just Announced!

Future Direction for Orphan Drugs in Europe

3 November 2010 I Paris, France

The conference will reflect on the experience gained in the first ten years of the European Orphan Medicinal Products regulation and provide an outlook on future developments. Learning and outcomes from the European Medicines Agency ten year celebration conference on Orphan Medicinal Products will also be shared.

Programme Co-Chairs

Catarina Edfjäll, Senior Director Head of Regulatory Strategy Europe, Celgene International SARL, Switzerland

Kerstin Westermark, Senior Expert, COMP Chairperson, Medical Products Agency, Sweden

Programme Committee

Emmanuel Chantelot, Executive Director, European Biopharmaceutical Enterprises

Wills Hughes-Wilson, Senior Director, Health Policy Europe, Genzyme, Belgium

Yann Le Cam, Chief Executive Officer, EURORDIS, France

Jordi Llinares, Head of Orphan Medicines European Medicines Agency, European Union

Key Topics

- Orphan Designation: What have we learned and what has changed in the course of the first 10 years?
- Marketing Authorisation for Orphan Drugs: Significant benefit, similarity, market exclusivity and other challenges
- Orphan Rewards and Incentives: What is the value of orphan designation?
- Market Access and HTA: Particular challenges and opportunities for orphan drugs
- Academia and Research

Who Will Attend

The aim of this one day conference is to bring together patients, industry and regulators to share experiences with the development of orphan medicinal products in Europe. Opportunities and challenges will be discussed while addressing various aspects from designation to market access of orphan medicinal products

FOR MORE INFORMATION PLEASE CONTACT
TAMARA.KOHLER@DIAEUROPE.ORG I +41 61 225 51 57

DIA®
www.diahome.org